Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP.
OBJECTIVE
To investigate the suppressive effect of nitric oxide (NO) on vascular endothelial growth factor (VEGF) gene expression and to elucidate its mechanism of action.


METHODS
Immortalized human retinal epithelial (RPE) cells, H-ras-transfected murine capillary endothelial cells, and nuclear factor-kappaB (NF-kappaB) RelA knockout 3T3 fibroblasts had VEGF gene expression stimulated by hypoxia, TPA (phorbol ester 12-O-tetradecanoylphorbol-13 acetate), and ras-transfection. The dose response and time course of inhibition of VEGF gene expression by NO were characterized by northern blot analysis, ribonuclease protection assay, and enzyme-linked immunosorbent assay. The effects of NF-kappaB and cGMP in the NO-induced suppression of VEGF gene expression were quantitated. cGMP production was inhibited by LY 83583 (6-anilino-5,8-quinolinedione), a specific inhibitor of guanylate cyclase production, and cGMP accumulation was quantitated by immunoassay. RelA knockout 3T3 fibroblasts were used to assess the contribution of NF-kappaB to the downregulation of VEGF by NO.


RESULTS
The NO donor sodium nitroprusside (SNP) decreased hypoxia-induced VEGF gene expression in a dose- and time-dependent manner. One hundred fifty micromolar SNP completely suppressed hypoxia-induced VEGF mRNA levels for at least 24 hours. Constitutive VEGF expression was not altered by SNP. The SNP-mediated decreases in VEGF expression were associated with increases in intracellular cGMP and were blocked by LY 83583. Sodium nitroprusside was able to decrease hypoxia-induced VEGF mRNA increases in fibroblasts deficient in the RelA subunit of NF-kappaB. Nitric oxide was also effective at suppressing increased VEGF expression secondan, to mutant ras and TPA.


CONCLUSIONS
These data indicate that NO decreases hypoxia-induced VEGF via a cGMP-dependent mechanism and suggest that NO may serve as an endogenous inhibitor of both hypoxia- and non- hypoxia-enhanced VEGF expression in vivo.
Ghiso
N
N
Department of Surgery, Children's Hospital, Boston, Massachusetts, USA.
Rohan
R M
RM
Amano
S
S
Garland
R
R
Adamis
A P
AP
D016475:3T3 Cells; D000818:Animals; D002460:Cell Line; D003563:Cyclic CMP / Q000502:physiology*; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000235:genetics*; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology*; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D000860:Hypoxia / Q000235:genetics*; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000235:genetics*; D051379:Mice; D016328:NF-kappa B / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D012160:Retina / Q000166:cytology / Q000502:physiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D016328:NF-kappa B; D020030:Nitric Oxide Donors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D009599:Nitroprusside; D009569:Nitric Oxide; D003563:Cyclic CMP; D013755:Tetradecanoylphorbol Acetate